banner

Investors

At ACADIA, we remain deeply committed to providing important new therapies to patients and delivering value for our stockholders. Our Investor Center is designed to provide you with convenient access to company information.

Recent News

12/04/19
- Pimavanserin met the primary endpoint in the study, significantly reducing the risk of relapse of psychosis by 2.8 fold (Hazard Ratio (HR)=0.353, one-sided p=0.0023) - Pimavanserin met the key secondary endpoint in the study, significantly reducing the risk of discontinuation for any reason by
11/25/19
- ACADIA to initiate second pivotal study in the first half of 2020 - Conference call and webcast to be held today at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Nov. 25, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced positive top-line results from its ADVANCE study, a
11/11/19
SAN DIEGO --(BUSINESS WIRE)--Nov. 11, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced it will host a live webcast of its investor event following the late-breaking oral presentation of the Phase 3 HARMONY results evaluating pimavanserin as a treatment for dementia-related